The week in pharma: action, reaction and insight – week to January 7, 2022

9 January 2022

By Barbara Obstoj-Cardwell. Editor

Licensing deals featured prominently in last week’s news, starting with Biogen last Tuesday saying it has exercised an option for rights to Ionis Pharmaceuticals’ BIIB115/ION306 for spinal muscular atrophy. Then US biotech giant Amgen inked an up to $1.9 billion agreement with machine learning start-up Generate Biomedicines to create new protein therapeutics. Also, US RNAi specialist Alnylam Pharmaceuticals signed a research collaboration with Swiss giant Novartis on therapies to restore liver function. And UK-based AstraZeneca signed a deal with Neurimmune for its rare disease candidate NI006 that could cost as much as $760 million.

Biogen takes another shot at spinal muscular atrophy

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK